| Tulelake Health Center | |
|
498 Main Street Tulelake CA 96134-0725 | |
| (530) 999-9060 | |
| (530) 667-2562 |
| Full Name | Tulelake Health Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 498 Main Street, Tulelake, California |
| Authorized Official Name and Position | Brandon Watkins (CFO) |
| Authorized Official Contact | 5309999010 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Tulelake Health Center Po Box 277 Bieber CA 96009-0277 Ph: (530) 999-9010 | Tulelake Health Center 498 Main Street Tulelake CA 96134-0725 Ph: (530) 999-9060 |
| NPI Number | 1679645121 |
|---|---|
| Provider Enumeration Date | 11/13/2006 |
| Last Update Date | 07/28/2023 |
| Medicare PECOS PAC ID | 4284685538 |
|---|---|
| Medicare Enrollment ID | O20111213000896 |
News Archive
Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.
Cervical cancer rates in the United States are higher than previously believed, particularly among 65- to 69-year-old women and African-American women, according to a study led by a researcher at the University of Maryland School of Medicine published in the journal Cancer.
The National Association of Drug Diversion Investigators (NADDI) – a nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion – today lauded the latest results achieved by the real-time, stop-sale system in North Carolina.
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679645121 | NPI | - | NPPES |
| 1679645121 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.
Cervical cancer rates in the United States are higher than previously believed, particularly among 65- to 69-year-old women and African-American women, according to a study led by a researcher at the University of Maryland School of Medicine published in the journal Cancer.
The National Association of Drug Diversion Investigators (NADDI) – a nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion – today lauded the latest results achieved by the real-time, stop-sale system in North Carolina.
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.
› Verified 8 days ago